Isolation, Chemical Characterization, and Quantitation of Aβ 3-Pyroglutamyl Peptide from Neuritic Plaques and Vascular Amyloid Deposits

Kuo, Yu-Min; Emmerling, Mark R.; Woods, Amina S.; Cotter, Robert J.; Roher, Alex E.

doi:10.1006/bbrc.1997.7083

Cited by 178Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Isolation, Chemical Characterization, and Quantitation of Aβ 3-Pyroglutamyl Peptide from Neuritic Plaques and Vascular Amyloid Deposits

Open access

Kuo, Yu-Min, Emmerling, Mark R., Woods, Amina S., Cotter, Robert J., Roher, Alex E.·1997·Biochemical and Biophysical Research Communications

DOI 10.1006/bbrc.1997.7083

Open this paper in CoChat — free account Open PDF

Abstract

From the neuritic plaques and vascular walls of the brains of patients with Alzheimer disease, we have purified and quantified an A beta peptide which starts at residue 3Glu in the form of pyroglutamyl (A beta3pE). The N-terminally truncated A beta3pE comprised 51% of the A beta in the neuritic plaques. This was followed by 30% starting at position 1Asp which included 20% in the isomerized form (IsoAsp). In contrast, the vascular amyloid only contained an average of 11% in the form of A beta3pE with the major component starting at residue 1Asp (69%), which included only 6% in the form of IsoAsp. The presence of A beta3pE has important structural consequences since it is more hydrophobic than other forms of A beta, thus increasing the insolubility of A beta. In addition, A beta3pE, with its blocked N-terminus to the action of common aminopeptidases, may result in the profuse accumulation of A beta in the neuritic plaques of Alzheimer disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1006/bbrc.1997.7083

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

pE3Aβ is present at low concentrations but is often associated with dense core plaques.
“The pE3Aβ is present at low concentrations, but often associated with dense core plaques 56,78 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [78]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · see citing works
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · see citing works
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417 · see citing works
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799 · see citing works
Self-citation
Amyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 798 · see citing works
beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.
Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., & Ball, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10836 · Cited by 740 · see citing works
Self-citation
Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · see citing works
Peptide Compositions of the Cerebrovascular and Senile Plaque Core Amyloid Deposits of Alzheimer′s Disease
Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., & Iqbal, K. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1112 · Cited by 510 · see citing works
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.
Mori, H., Takio, K., OGAWARA, M., & Selkoe, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41896-0 · Cited by 481 · see citing works
Relative Abundance of Alzheimer A Beta Amyloid Peptide Variants in Alzheimer Disease and normal Aging
Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468 · see citing works
Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists.
Mirra, S. S., Hart, M. N., & Terry, R. D. (1993) · PubMed · Cited by 412 · see citing works
Aggregation of Secreted Amyloid β-Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture
Podlisny, M. B., Ostaszewski, B. L., Squazzo, S. L., Koo, E. H., Rydel, R. E., Teplow, D. B., & Selkoe, D. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.16.9564 · Cited by 364 · see citing works
Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro
Pike, C. J., Overman, M. J., & Cotman, C. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23895 · Cited by 302 · see citing works
The Profile of Soluble Amyloid β Protein in Cultured Cell Media
Wang, R., Sweeney, D. A., Gandy, S., & Sisodia, S. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31894 · Cited by 293 · see citing works
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques.
Iwatsubo, T., Saido, T. C., Mann, D. M. A., Lee, V. M.-Y., & Trojanowski, J. Q. (1996) · Europe PMC (PubMed Central) · Cited by 248 · see citing works
Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging
Joachim, C. L., Duffy, L. K., Morris, J. H., & Selkoe, D. J. (1988) · Brain Research · doi:10.1016/0006-8993(88)90673-7 · Cited by 180 · see citing works
Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues.
Tomiyama, T., Asano, S., Furiya, Y., Shirasawa, T., Endo, N., & Mori, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34045-0 · Cited by 154 · see citing works
Nontoxic Amyloid β Peptide1-42 Suppresses Acetylcholine Synthesis
Hoshi, M. M., Takashima, A., Murayama, M., Yasutake, K., Yoshida, N., Ishiguro, K., Hoshino, T., & Imahori, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2038 · Cited by 151 · see citing works
Degradation of Amyloid β-Protein by a Serine Protease-α2-Macroglobulin Complex
Qiu, W. Q., Borth, W., Ye, Z., Haass, C., Teplow, D. B., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8443 · Cited by 98 · see citing works
Amyloid β-Protein Aggregation Nullifies Its Pathologic Properties in Cultured Cerebrovascular Smooth Muscle Cells
Davis-Salinas, J., & Nostrand, W. E. V. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.20887 · Cited by 74 · see citing works
Secretion of beta-amyloid precursor protein involves multiple cleavage sites.
Zhong, Z., Higaki, J. N., Murakami, K., Wang, Y., Catalano, R., Quon, D. H., & Cordell, B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42395-7 · Cited by 69 · see citing works
Microglial cells and amyloid ? protein (A?) deposition: association with A?40-plaques
Mann, D. M. A., Iwatsubo, T., Fukumoto, H., Ihara, Y., Odaka, A., & Suzuki, N. (1995) · Acta Neuropathologica · doi:10.1007/bf00294808 · Cited by 40 · see citing works
The effects of aspartic acid‐bond isomerization on in vitro properties of the amyloid β‐peptide as modeled with N‐terminal decapeptide fragments
Szendrei, G. I., Prammer, K. V., VASKO, M., LEE, V. M. ‐., & Ötvös, L. (1996) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1996.tb01358.x · Cited by 27 · see citing works
Comparison of major cortical aminopeptidase activity in normal brain and brain from patients with Alzheimer's disease
Mantle, D., Lauffart, B., Perry, E. K., & Perry, R. H. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90024-5 · Cited by 21 · see citing works
Purification and characterization of pyroglutamyl aminopeptidase from human cerebral cortex
Lauffart, B., MCDERMOTT, J. R., Biggins, J. A., GIBSON, A. M., & Mantle, D. (1989) · Biochemical Society Transactions · doi:10.1042/bst0170207 · Cited by 13 · see citing works

Flagged first, then by citations

Research works printed but not linked: 5

R. J., Gowing, E., and Ball, M. J. (1993) Proc. Natl. Acad. Sci.
served that N-terminal truncation also renders Ab less USA 90, 10836-10840. able to activate complement (27). Thus, N-terminal 9. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., Mc- truncation may confer a degree of protection to brains Donald, B. L., and Beyreuther, K. (1985) Proc. Natl. Acad. Sci. in which Ab1-42 is made. The absence of inflammatory USA 82, 4245-4249. reactions around early plaques in Down's syndrome 10. Joachim, C. L., Duffy, K. L., Morris, J. H., and Selkoe, D. J. (1988) Brain Res. 474, 100-111.
which reportedly are composed of Ab3pE-42 (14), 11. Miller, D. L., Papayannopoulos, I. A., Styles, J., Bovin, S. A., Lin, may suggest that N-terminal truncation of Ab1-42 rep- Y. Y., Bieman, K., and Iqbl, K. (1983) Arch. Biochem. Biophys. resents a means of defense in the brain parenchyma. 301, 41-52. The presence of pyroglutamyl and aspartyl isomer- 12. Naslund, J., Shierhorn, A., Hellman, U., Lannfelt, L., Roses, izations, which are the predominant modifications ob- A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., served in the cores of amyloid of neuritic plaques, ap- Greengard, P., Nordstedt, C., and Terenius, L. (1994) Proc. Natl. Acad. Sci. USA 91, 8378-8382. parently increase the insolubility and resistance of Ab 13. Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, peptides to proteolytic degradation. If these modifica- Y., and Kawashima, S. (1995) Neuron 14, 457-466.
Lauffart, B., McDermott, J. R., Biggins, J. A., Gibson, A. M., and yloid accumulation in the Alzheimer disease brain. Mantle, D. (1988) Biochem. Soc. Trans. 17, 207-208.
ling, M. R. (1997) Amyloid, in Press. Lab. Med. 117, 132-144.

Sorted by citations

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654 · see citing works
Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease.
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.027 · Cited by 623 · see citing works
“, 2006), stronger hydrophobicity (Kuo et al., 1997), and increased toxicity compared with full-length A (Russo et al.”
Background
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626 · see citing works
<scp>A</scp>rizona <scp>S</scp>tudy of <scp>A</scp>ging and <scp>N</scp>eurodegenerative <scp>D</scp>isorders and <scp>B</scp>rain and <scp>B</scp>ody <scp>D</scp>onation <scp>P</scp>rogram
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460 · see citing works
Self-citation
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · see citing works
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455 · see citing works
Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease
Golde, T. E., Eckman, C. B., & Younkin, S. G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00043-0 · Cited by 300 · see citing works
Structural and kinetic features of amyloid β-protein fibrillogenesis
Teplow, D. B. (1998) · Amyloid · doi:10.3109/13506129808995290 · Cited by 280 · see citing works
Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains
Kuo, Y., Kokjohn, T. A., Beach, T. G., Sue, L. I., Brune, D. C., Lopez, J. C., Kalback, W. M., Abramowski, D., Sturchler, C., Staufenbiel, M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007859200 · Cited by 245 · see citing works
Self-citation
Isoaspartate Formation and Neurodegeneration in Alzheimer's Disease
Shimizu, T., Watanabe, A., OGAWARA, M., Mori, H., & Shirasawa, T. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1955 · Cited by 214 · see citing works
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201 · see citing works
Pyroglutamate‐modified amyloid β‐peptides – AβN3(pE) – strongly affect cultured neuron and astrocyte survival
Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D’Arrigo, C., Patrone, E., Carlo, P., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01107.x · Cited by 201 · see citing works
Biological Significance of Isoaspartate and Its Repair System
Shimizu, T., Matsuoka, Y., & Shirasawa, T. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1590 · Cited by 198 · see citing works
Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients
Patton, R., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Vickle, G. D. V., Luehrs, D. C., Kuo, Y., Lopez, J. C., Brune, D. C., Ferrer, I., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192 · see citing works
Self-citation
High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's Disease
Kuo, Y., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., & Roher, A. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0552 · Cited by 182 · see citing works
Self-citation
Phosphorylation of amyloid beta (Aβ) peptides – A trigger for formation of toxic aggregates in Alzheimer's disease
Kumar, S., & Walter, J. (2011) · Aging · doi:10.18632/aging.100362 · Cited by 181 · see citing works
Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.-U., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0557-5 · Cited by 174 · see citing works
Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-10422-x · Cited by 164 · see citing works
Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide
Ward, R. V., JENNINGS, K. H., Jepras, R., Neville, W. A., OWEN, D. E., HAWKINS, J., Christie, G., Davis, J. B., George, A. R., Karran, E. H., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480137 · Cited by 153 · see citing works
Structure and function of amyloid in Alzheimer's disease
Morgan, C., Colombres, M., Núñez, M. T., & Inestrosa, N. C. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.10.004 · Cited by 136 · see citing works
Physicochemical characteristics of soluble oligomeric Aβand their pathologic role in Alzheimer's disease
Watson, D., Castaño, E., Kokjohn, T. A., Kuo, Y., Lyubchenko, Y. L., Pinsky, D. J., Connolly, E. S., Esh, C. L., Luehrs, D. C., Stine, W. B., et al. (2005) · Neurological Research · doi:10.1179/016164105x49436 · Cited by 129 · see citing works
Self-citation
Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease
Shimizu, T., Fukuda, H., Murayama, S., Izumiyama, N., & Shirasawa, T. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10350 · Cited by 128 · see citing works
Elevation of β-Amyloid Peptide 2–42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells
Wiltfang, J., Esselmann, H., Cupers, P., Neumann, M., Kretzschmar, H. A., Beyermann, M., Schleuder, D., Jahn, H., Rüther, E., Kornhuber, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102790200 · Cited by 126 · see citing works
Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: Implications for the study of amyloid formation
Nilsson, M. R., Driscoll, M., & Raleigh, D. P. (2002) · Protein Science · doi:10.1110/ps.48702 · Cited by 124 · see citing works
Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease
Kuo, Y.-M., Webster, S., Emmerling, M. R., De Lima, N., & Roher, A. E. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00014-3 · Cited by 122 · see citing works
Self-citation
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions
Kokjohn, T. A., & Roher, A. E. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.03.002 · Cited by 122 · see citing works
Self-citation
APP/Aβ structural diversity and Alzheimer's disease pathogenesis
Roher, A. E., Kokjohn, T. A., Clarke, S. G., Sierks, M. R., Maarouf, C. L., Serrano, G. E., Sabbagh, M., & Beach, T. G. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.007 · Cited by 121 · see citing works
Self-citation
Amyloidogenic Processing of Amyloid Precursor Protein: Evidence of a Pivotal Role of Glutaminyl Cyclase in Generation of Pyroglutamate-Modified Amyloid-β
Cynis, H., Scheel, E., Saido, T. C., Schilling, S., & Demuth, H. (2008) · Biochemistry · doi:10.1021/bi800250p · Cited by 117 · see citing works
Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 71 · see citing works
Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation
Huang, K.-F., Liu, Y., Cheng, W.-J., Ko, T., & Wang, A. H. ‐. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504184102 · Cited by 112 · see citing works
Porphyromonas gingivalis Infection Induces Amyloid-β Accumulation in Monocytes/Macrophages
Nie, R., Wu, Z., Ni, J., Zeng, F., Yu, W., Zhang, Y., Kadowaki, T., Kashiwazaki, H., Teeling, J. L., & Zhou, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190298 · Cited by 112 · see citing works
Reconsider Alzheimer's disease by the ‘calpain–cathepsin hypothesis’—A perspective review
Yamashima, T. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.004 · Cited by 107 · see citing works
Aminopeptidase A contributes to the N‐terminal truncation of amyloid β‐peptide
Sévalle, J., Amoyel, A., Robert, P. H., Fournié‐Zaluski, M., Roques, B. P., & Checler, F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05950.x · Cited by 108 · see citing works
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawhar, S., Lucassen, P. J., Multhaup, G., Brody, D. L., Esparza, T., Ingelsson, M., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-009-0314-x · Cited by 106 · see citing works
Overexpression of Glutaminyl Cyclase, the Enzyme Responsible for Pyroglutamate Aβ Formation, Induces Behavioral Deficits, and Glutaminyl Cyclase Knock-out Rescues the Behavioral Phenotype in 5XFAD Mice
Jawhar, S., Wirths, O., Schilling, S., Graubner, S., Demuth, H., & Bayer, T. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.185819 · Cited by 105 · see citing works
Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution
Schilling, S., Wasternack, C., & Demuth, H. (2008) · Biological Chemistry · doi:10.1515/bc.2008.111 · Cited by 102 · see citing works
Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease
Saido, T. C., & Iwata, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.12.015 · Cited by 101 · see citing works
The amyloid‐β peptide and its role in Alzheimer's disease
Clippingdale, A. B., Wade, J. D., & Barrow, C. J. (2001) · Journal of Peptide Science · doi:10.1002/psc.324 · Cited by 97 · see citing works
Hemoglobin promotes A? oligomer formation and localizes in neurons and amyloid deposits
Wu, C.-Y., LIAO, P., Yu, L., WANG, S., CHEN, S., Wu, C.-Y., & Kuo, Y. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.014 · Cited by 96 · see citing works
Self-citation
Peripherally Applied Synthetic Peptide isoAsp7-Aβ(1-42) Triggers Cerebral β-Amyloidosis
Kozin, S. A., Cheglakov, I. B., Ovsepyan, A. A., Telegin, G. B., Tsvetkov, P. O., Лисица, А. В., & Makarov, A. А. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9399-y · Cited by 95 · see citing works
In vivo mapping of amyloid toxicity in Alzheimer disease
Frisoni, G. B., Lorenzi, M., Caroli, A., Kemppainen, N. M., Någren, K., & Rinne, J. O. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e896 · Cited by 96 · see citing works
Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease
Liu, K., Solano, I., Mann, D. M. A., Lemere, C. A., Mercken, M. H., Trojanowski, J. Q., & Lee, V. M. ‐. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0077-5 · Cited by 94 · see citing works
N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis
Youssef, I., Florent‐Béchard, S., Malaplate, C., Koziel, V., Bihain, B. E., Olivier, J. L., Leininger‐Muller, B., Kriem, B., Oster, T., & Pillot, T. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.005 · Cited by 89 · see citing works
Oligomerization and fibril assembly of the amyloid-β protein
Roher, A. E., Baudry, J. Y., Chaney, M. O., Kuo, Y., Stine, W. B., & Emmerling, M. R. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00030-2 · Cited by 87 · see citing works
Self-citation
Alternative pathways for production of β-amyloid peptides of Alzheimer's disease
HOOK, V. Y. H., Schechter, I., Demuth, H., & Hook, G. (2008) · Biological Chemistry · doi:10.1515/bc.2008.124 · Cited by 82 · see citing works
Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s Disease—Studies on Relation to Effective Target Occupancy
Hoffmann, T., Meyer, A., Heiser, U. F., Kurat, S., Böhme, L., Kleinschmidt, M., Bühring, K. U., Hutter‐Paier, B., Farcher, M., Demuth, H., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240614 · Cited by 78 · see citing works
Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease
Wittnam, J. L., Portelius, E., Zetterberg, H., Gustavsson, M. K., Schilling, S., Koch, B. C. P., Demuth, H., Blennow, K., Wirths, O., & Bayer, T. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308601 · Cited by 77 · see citing works
Inhibition of glutaminyl cyclase prevents pGlu‐Aβ formation after intracortical/hippocampal microinjection in vivo/in situ
Schilling, S., Appl, T., Hoffmann, T., Cynis, H., Schulz, K., Jagla, W., Friedrich, D., Wermann, M., Buchholz, M., Heiser, U. F., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05471.x · Cited by 76 · see citing works
Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer’s disease pathology
Michno, W., Nyström, S., Wehrli, P. M., Lashley, T., Brinkmalm, G., Guérard, L., Syvänen, S., Sehlin, D., Kaya, I., Brinet, D., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006604 · Cited by 73 · see citing works
Identification of Amino-Terminally and Phosphotyrosine-Modified Carboxy-Terminal Fragments of the Amyloid Precursor Protein in Alzheimer's Disease and Down's Syndrome Brain
Russo, C., Salis, S., Dolcini, V., Venezia, V., Song, X., Teller, J. K., & Schettini, G. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0357 · Cited by 75 · see citing works
Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.
Howlett (2008) · PubMed · doi:10.14670/hh-23.67 · Cited by 65 · see citing works
β-Amyloid Peptide Variants in Brains and Cerebrospinal Fluid from Amyloid Precursor Protein (APP) Transgenic Mice
Schieb, H., Kratzin, H., Jahn, O., Möbius, W., Rabe, S., Staufenbiel, M., Wiltfang, J., & Klafki, H. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.246561 · Cited by 65 · see citing works
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
Pérez-Garmendia, R., & Gevorkian, G. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311050004 · Cited by 65 · see citing works
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 66 · see citing works
Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders
Virdee, K., Cumming, P. D., Caprioli, D., Jupp, B., Rominger, A., Aigbirhio, F. I., Fryer, T. D., Riss, P. J., & Dalley, J. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.01.009 · Cited by 60 · see citing works
Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets
Kokjohn, T. A., Vickle, G. D. V., Maarouf, C. L., Kalback, W. M., Hunter, J. M., Daugs, I. D., Luehrs, D. C., Lopez, J. C., Brune, D. C., Sue, L. I., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.004 · Cited by 60 · see citing works
Self-citation
Kinetic analysis of β-amyloid peptide aggregation induced by metal ions based on surface plasmon resonance biosensing
Hu, W.-P., Chang, G., Chen, S.-J., & Kuo, Y. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2005.12.016 · Cited by 58 · see citing works
Self-citation
Imaging Alzheimer's disease pathology: one target, many ligands
Lockhart, A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.008 · Cited by 56 · see citing works
β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease
Dumery, L., Bourdel, F., Soussan, Y., Fialkowsky, A., Viale, S., Nicolas, P., & Reboud‐Ravaux, M. (2001) · Pathologie Biologie · doi:10.1016/s0369-8114(00)00009-2 · Cited by 55 · see citing works
Enhanced Fibril Fragmentation of N‐Terminally Truncated and Pyroglutamyl‐Modified Aβ Peptides
Wulff, M., Baumann, M., Thümmler, A., Yadav, J. K., Heinrich, L., Knüpfer, U., Schlenzig, D., Schierhorn, A., Rahfeld, J., Horn, U., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511099 · Cited by 53 · see citing works
Iowa Variant of Familial Alzheimer’s Disease
Tomidokoro, Y., Rostagno, A. A., Neubert, T. A., Lu, Y., Rebeck, G. W., Frangione, B., Greenberg, S. M., & Ghiso, J. A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090636 · Cited by 53 · see citing works
Molecular basis for chirality-regulated Aβ self-assembly and receptor recognition revealed by ion mobility-mass spectrometry
Li, G., DeLaney, K., & Li, L. (2019) · Nature Communications · doi:10.1038/s41467-019-12346-8 · Cited by 52 · see citing works
Simultaneous Determination of Post-Translational Racemization and Isomerization of N-Terminal Amyloid-β in Alzheimer’s Brain Tissues by Covalent Chiral Derivatized Ultraperformance Liquid Chromatography Tandem Mass Spectrometry
Inoue, K., Hosaka, D., Mochizuki, N., Akatsu, H., Tsutsumiuchi, K., Hashizume, Y., Matsukawa, N., Yamamoto, T., & Toyo’oka, T. (2013) · Analytical Chemistry · doi:10.1021/ac403315h · Cited by 50 · see citing works
Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease
Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., McLean, C., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2021) · Brain Communications · doi:10.1093/braincomms/fcab028 · Cited by 50 · see citing works
Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease
Rosen, R. F., Tomidokoro, Y., Farberg, A. S., Dooyema, J., Ciliax, B., Preuss, T. M., Neubert, T. A., Ghiso, J. A., LeVine, H., & Walker, L. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.019 · Cited by 46 · see citing works
Isolation and Biochemical Characterization of Amyloid Plaques and Paired Helical Filaments
Rostagno, A. A., & Ghiso, J. A. (2009) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0333s44 · Cited by 44 · see citing works
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Schilling, S., Rahfeld, J., Lues, I., & Lemere, C. A. (2018) · Molecules · doi:10.3390/molecules23051068 · Cited by 45 · see citing works
The biochemical aftermath of anti-amyloid immunotherapy
Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Kalback, W. M., Patton, R., Luehrs, D. C., Masliah, E., Nicoll, J. A. R., Sabbagh, M. N., Beach, T. G., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-39 · Cited by 43 · see citing works
Self-citation
Congophilicity (Congo red affinity) of different β2-microglobulin conformations characterized by dye affinity capillary electrophoresis
Heegaard, N. H. H., Sen, J. W., & Nissen, M. H. (2000) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)00579-3 · Cited by 43 · see citing works
Analysis of Amino-Terminal Variants of Amyloid-β Peptides by Capillary Isoelectric Focusing Immunoassay
Haußmann, U., Jahn, O., Linning, P., Janßen, C., Liepold, T., Portelius, E., Zetterberg, H., Bauer, C., Schuchhardt, J., Knölker, H., et al. (2013) · Analytical Chemistry · doi:10.1021/ac401055y · Cited by 42 · see citing works
Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease
Basi, G. S., Feinberg, H., Oshidari, F., Anderson, J., Barbour, R., Baker, J., Comery, T. A., Diep, L., Gill, D. S., Johnson‐Wood, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045187 · Cited by 45 · see citing works
Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie · doi:10.1002/ange.200802808 · Cited by 40 · see citing works
Isoaspartate residues dramatically influence substrate recognition and turnover by proteases
Böhme, L., Bär, J. W., Hoffmann, T., Manhart, S., Ludwig, H., Rosche, F., & Demuth, H. (2008) · Biological Chemistry · doi:10.1515/bc.2008.123 · Cited by 38 · see citing works
Cell-derived soluble oligomers of human amyloid-β peptides disturb cellular homeostasis and induce apoptosis in primary hippocampal neurons
Yang, T.-T., Hsu, C.-T., & Kuo, Y. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0311-0 · Cited by 37 · see citing works
Self-citation
Complete identification of all 20 relevant epimeric peptides in β-amyloid: a new HPLC-MS based analytical strategy for Alzheimer's research
Du, S., Readel, E. R., Wey, M., & Armstrong, D. W. (2020) · Chemical Communications · doi:10.1039/c9cc09080k · Cited by 34 · see citing works
Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
Roher, A. E., Cribbs, D. H., Kim, R. C., Maarouf, C. L., Whiteside, C. M., Kokjohn, T. A., Daugs, I. D., Head, E., Liebsack, C., Serrano, G. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059735 · Cited by 34 · see citing works
Self-citation
A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
Hartlage‐Rübsamen, M., Bluhm, A., Moceri, S., Machner, L., Köppen, J., Schenk, M., Hilbrich, I., Holzer, M., Weidenfeller, M., Richter, F., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02349-5 · Cited by 31 · see citing works
Pyroglutamate-Modified Amyloid-β Protein Demonstrates Similar Properties in an Alzheimer's Disease Familial Mutant Knock-In Mouse and Alzheimer's Disease Brain
Wu, G., Miller, R. A., Connolly, B., Marcus, J., Renger, J. J., & Savage, M. J. (2013) · Neurodegenerative Diseases · doi:10.1159/000353634 · Cited by 31 · see citing works
Isoaspartate containing amyloid precursor protein derived peptides alter efficacy and specificity of potential β-secretases
Böhme, L., Hoffmann, T., Manhart, S., Wolf, R., & Demuth, H. (2008) · Biological Chemistry · doi:10.1515/bc.2008.125 · Cited by 31 · see citing works
Citrullination of Amyloid-β Peptides in Alzheimer’s Disease
Mukherjee, S., Perez, K. A., Dubois, C., Nisbet, R. M., Li, Q., Varghese, S., Jin, L., Birchall, I. E., Streltsov, V. A., Vella, L. J., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00474 · Cited by 29 · see citing works
Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease
Marcello, A., Wirths, O., Schneider-Axmann, T., Degerman-Gunnarsson, M., Lannfelt, L., & Bayer, T. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.011 · Cited by 29 · see citing works
Concomitant detection of β-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice
Härtig, W., Goldhammer, S., Bauer, U. U. I., Wegner, F., Wirths, O., Bayer, T. A., & Grosche, J. (2010) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2010.03.006 · Cited by 29 · see citing works
Hydrogen exchange studies on Alzheimer's amyloid‐β peptides by mass spectrometry using matrix‐assisted laser desorption/ionization and electrospray ionization
Kraus, M., Bienert, M., & Krause, E. (2002) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.901 · Cited by 29 · see citing works
The Human Amyloid-β Precursor Protein770 Mutation V717F Generates Peptides Longer Than Amyloid-β-(40-42) and Flocculent Amyloid Aggregates
Roher, A. E., Kokjohn, T. A., Esh, C. L., Weiss, N., Childress, J., Kalback, W. M., Luehrs, D. C., Lopez, J. C., Brune, D. C., Kuo, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311380200 · Cited by 29 · see citing works
Self-citation
Generation of amyloid β peptide with pyroglutamate at position 3 in primary cortical neurons
Shirotani, K., Tsubuki, S., Lee, H.-J., Maruyama, K., & Saido, T. C. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00351-8 · Cited by 28 · see citing works
Chemical Strategies for Controlling Protein Folding and Elucidating the Molecular Mechanisms of Amyloid Formation and Toxicity
Butterfield, S. M., Hejjaoui, M., Fauvet, B., Awad, L., & Lashuel, H. A. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.051 · Cited by 27 · see citing works
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms
Wildburger, N. C., Hartke, A.-S., Schidlitzki, A., & Richter, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.598446 · Cited by 26 · see citing works
Characterisation of the binding of amyloid imaging tracers to rodent Aβ fibrils and rodent-human Aβ co-polymers
Ye, L., Morgenstern, J. L., Lamb, J. R., & Lockhart, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.126 · Cited by 27 · see citing works
Neuropathology and Amyloid-β Spectrum in a Bapineuzumab Immunotherapy Recipient
Roher, A. E., Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Hunter, J. M., Sabbagh, M. N., & Beach, T. G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101809 · Cited by 26 · see citing works
Self-citation
Immunodominant epitope and properties of pyroglutamate-modified Aβ-specific antibodies produced in rabbits
Acero, G., Manoutcharian, K., Vasilevko, V., Munguía, M. E., Govezensky, T., Coronas, G., Luz-Madrigal, A., Cribbs, D. H., & Gevorkian, G. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.06.003 · Cited by 26 · see citing works
13 Protein L-isoaspartyl, D-aspartyl O-methyltransferases: Catalysts for protein repair
O’Connor, C. M. (2006) · The Enzymes · doi:10.1016/s1874-6047(06)80015-6 · Cited by 25 · see citing works
Presenilin-1 280Glu→Ala Mutation Alters C-Terminal APP Processing Yielding Longer Aβ Peptides: Implications for Alzheimer’s Disease
Vickle, G. D. V., Esh, C. L., Kokjohn, T. A., Patton, R., Kalback, W. M., Luehrs, D. C., Beach, T. G., Newell, A., Lopera, F. J., Ghetti, B. F., et al. (2008) · Molecular Medicine · doi:10.2119/2007-00094.vanvickle · Cited by 25 · see citing works
Self-citation
Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases
Zhang, Y., Wang, Y., Zhao, Z., Peng, W., Wang, P., Xu, X., & Zhao, C. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175178 · Cited by 25 · see citing works
Aminopeptidase A contributes to biochemical, anatomical and cognitive defects in Alzheimer’s disease (AD) mouse model and is increased at early stage in sporadic AD brain
Valverde, A., Dunys, J., Lorivel, T., Debayle, D., Gay, A.-S., Lacas-Gervais, S., Roques, B., Chami, M., & Checler, F. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02308-0 · Cited by 21 · see citing works
Probing and Trapping a Sensitive Conformation: Amyloid-β Fibrils, Oligomers, and Dimers
Fawver, J. N., Duong, K. T., Wise-Scira, O., Chapa, R. P., Schall, H. E., Coskuner‐Weber, O., Zhu, X., Colom, L. V., & Murray, I. V. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120880 · Cited by 24 · see citing works
Computational evidence for the catalytic mechanism of glutaminyl cyclase. A DFT investigation
Calvaresi, M., Garavelli, M., & Bottoni, A. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22061 · Cited by 23 · see citing works
Role of Biochemical Alzheimer's Disease Biomarkers as End Points in Clinical Trials
Siemers, E., Demattos, R. B., May, P. C., & Dean, R. A. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.85 · Cited by 23 · see citing works
Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
Dammers, C., Gremer, L., Neudecker, P., Demuth, H., Schwarten, M., & Willbold, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139710 · Cited by 22 · see citing works
Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease
Han, S.-H., & Mook‐Jung, I. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.7.893 · Cited by 22 · see citing works

Amyloid β Protein Starting Pyroglutamate at Position 3 Is a Major Component of the Amyloid Deposits in the Alzheimer's Disease Brain
Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202 · see citing works
The Aβ 3-Pyroglutamyl and 11-Pyroglutamyl Peptides Found in Senile Plaque Have Greater β-Sheet Forming and Aggregation Propensities in Vitro than Full-Length Aβ
He, W., & Barrow, C. J. (1999) · Biochemistry · doi:10.1021/bi990563r · Cited by 216 · see citing works
P1‐434: Accumulation of Aβ starting with pyroglutamate at position 3 in the brain and its impact on amyloid pathology of Alzheimer's disease
Iwata, N., Tsubuki, S., Higuchi, M., Watanabe, K., Staufenbiel, M., Mann, D. M. A., & Saido, T. C. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1016
beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.
Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., & Ball, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10836 · Cited by 740 · see citing works
Self-citation
A pathogenic mechanism of N-terminally pyroglutamylated A^|^beta; and possible application of Alzheimer's disease by inhibition of the pyroglutamylation
Iwata, N., & Asai, M. (2012) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.52.1162

Authors: Kuo, Y.-M., Emmerling, M. R., Woods, A. S., Cotter, R. J., & Roher, A. E.
Affiliations: Banner Sun Health Research Institute (US)
Pfizer (United States) (US)
Johns Hopkins University (US)
Corresponding author: Roher, Alex E.
ORCID: Kuo, Yu-Min
Woods, Amina S.
Cotter, Robert J.
Venue: Biochemical and Biophysical Research Communications
Publisher: Elsevier BV
Published: 1997-08
Volume: 237
Issue: 1
Pages: 188-191
ISSN: 0006-291X (ISSN-L)
DOI: 10.1006/bbrc.1997.7083
OpenAlex: W2100791245
Cited by: 178
References: 25
Citations by year: 2026: 5 · 2025: 4 · 2024: 7 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 3 · 2013: 8 · 2012: 6
FWCI: 2.64
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1758 d)
Locations: Biochemical and Biophysical Research Communications (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01gm054882-04, 5r01ag011925-05, AG-11925)
National Institute on Aging (AG-11925)
National Institute of General Medical Sciences (GM-54882)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: amyloid-beta, Alzheimer's disease, neuritic plaques, vascular amyloid deposits, N-terminal truncation, peptide hydrophobicity, amyloid accumulation
MeSH terms: Alzheimer Disease, Amino Acid Sequence, Aminopeptidases, Amyloid, Blood Vessels, Brain, Brain Chemistry, Chromatography, High Pressure Liquid, Humans, Peptide Fragments, Mass Spectrometry, Trypsin, Amyloid beta-Peptides, Neurites

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Isolation, Chemical Characterization, and Quantitation of Aβ 3-Pyroglutamyl Peptide from Neuritic Plaques and Vascular Amyloid Deposits

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks